WP
TBPH icon

Woodline Partners’s Theravance Biopharma TBPH Stock Holding History

Woodline Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,122
Closed -$489K – 1143
2026
Q1 		$489K Buy
+30,122
New +$533K ﹤0.01% 970
2022
Q4 		– Sell
-119,854
Closed -$1.22M – 841
2022
Q3 		$1.22M Sell
119,854
-2,123,619
-95% -$19.9M 0.02% 522
2022
Q2 		$20.3M Buy
2,243,473
+916,820
+69% +$8.45M 0.31% 97
2022
Q1 		$12.7M Buy
1,326,653
+751,540
+131% +$7.36M 0.21% 151
2021
Q4 		$6.36M Sell
575,113
-1,404,017
-71% -$12.2M 0.09% 256
2021
Q3 		$14.6M Buy
1,979,130
+1,604,218
+428% +$17.9M 0.24% 117
2021
Q2 		$5.44M Buy
+374,912
New +$7.04M 0.1% 209

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Woodline Partners's TBPH Position: Q2 2026 in Review

Woodline Partners sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 30,122 shares — an estimated $489K sold.

Woodline Partners first reported a position in TBPH in Q2 2021 and held it in 7 quarters. The position peaked at $20.3M in Q2 2022. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Woodline Partners reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 30,122 Theravance Biopharma shares in Q2 2026, an estimated $489K.
  • Woodline Partners first reported a position in Theravance Biopharma in Q2 2021 and held it in 7 quarters.
  • Woodline Partners's Theravance Biopharma position peaked at $20.3M in Q2 2022.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.